Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

BusinesswireNov 26 21:45

Express News | Lantern Pharma & Starlight Therapeutics Present LP-184 (Star-001) Phase 1B Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (Sno) 2024 Highlighting Novel Synthetic Lethality

BreakingsNov 26 21:45

Express News | Lantern Pharma Announces First Patient Dosed in Japan for the Expansion Cohort in the Phase 2 Harmonic™ Clinical Trial of LP-300 in Never-Smoker Nsclc Patients

BreakingsNov 19 21:00

Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript

Earnings Call TranscriptsNov 9 08:23

Lantern Pharma Advances AI-Driven Cancer Therapies

TipRanksNov 8 12:48

Lantern Pharma 3Q Loss/Shr 42c >LTRN

Dow JonesNov 8 06:37